[ad_1] Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of […]
Tag: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
[ad_1] DUBLIN, Sept. 4, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the “notes”) in a private […]
